More Drug Does Not Always Lead to More Efficacy: Dr Mark Bleackley on the Progress of ...
Mark Bleackley discusses challenges in developing IHL-42X for obstructive sleep apnea (OSA), including lack of a standard for clinical trial endpoints. Adverse events observed were consistent with known effects of THC and acetazolamide, mitigated by dose reduction. Surprising findings included a nonlinear dose response in efficacy.
Reference News
More Drug Does Not Always Lead to More Efficacy: Dr Mark Bleackley on the Progress of ...
Mark Bleackley discusses challenges in developing IHL-42X for obstructive sleep apnea (OSA), including lack of a standard for clinical trial endpoints. Adverse events observed were consistent with known effects of THC and acetazolamide, mitigated by dose reduction. Surprising findings included a nonlinear dose response in efficacy.